$15.90
+0.0000%SWK Holdings Corporation, a specialty finance company that focuses on the healthcare sector. It operates in two segments, Finance Receivables and Pharmaceutical Development. The company provides customized financing solutions to a range of life science companies, including companies in the biotechnology, medical device, medical diagnostics and related tools, animal health, and pharmaceutical industries, as well as institutions and inventors. It also offers non-discretionary investment advisory services to institutional clients in separately managed accounts to invest in life science finance. In addition, the company engages in the pharmaceutical development, formulation and manufacturing, and licensing business through the Peptelligence platform. Further, it intends to out-license its internal product pipeline to create novel formulations using its proprietary technology to develop treatments for patients and caregivers. The company was formerly known as Kana Software, Inc. and changed its name to SWK Holdings Corporation in December 2009. SWK Holdings Corporation was founded in 1996 and is headquartered in Dallas, Texas.
Chief Executive Officer & President
Compensation
$835,700
Chief Financial Officer and Principal Financial & Accounting Officer
Compensation
$286,793
Controller
Director of Underwriting
General Counsel & Secretary
During the last 12 months, insiders have purchased $165K worth of SWKH shares, with no selling activity reported.
0
0.00
0
0.00
+0
+$0
0
0.00
0
0.00
+0
+$0
0
0.00
0
0.00
+0
+$0
11.6K
165.04K
0
0.00
+165K
+$165K
Albright Jerry
Director
$55K
Hatcher Robert K.
Director
$55K
Dotter Laurie L.
Director
$55K
No selling activity
Strong bullish signal with $165K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
3 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SWKH - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2024 N/A | April 29, 2025 | December 31, 2024 | 2024 | |
DEF 14A DEF 14A 2024 N/A | April 26, 2024 | June 14, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | May 01, 2023 | June 14, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | July 18, 2022 | August 10, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | June 07, 2021 | June 17, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 29, 2020 | May 18, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | October 25, 2019 | November 19, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 23, 2018 | May 21, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | April 21, 2017 | May 22, 2017 | 2017 | |
DEF 14A DEF 14A 2016 N/A | May 09, 2016 | May 31, 2016 | 2016 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.